ECSP099062A - Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a - Google Patents

Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Info

Publication number
ECSP099062A
ECSP099062A EC2009009062A ECSP099062A ECSP099062A EC SP099062 A ECSP099062 A EC SP099062A EC 2009009062 A EC2009009062 A EC 2009009062A EC SP099062 A ECSP099062 A EC SP099062A EC SP099062 A ECSP099062 A EC SP099062A
Authority
EC
Ecuador
Prior art keywords
aminopiridine
novedous
aurora
derivatives
inhibitory action
Prior art date
Application number
EC2009009062A
Other languages
English (en)
Inventor
Katsumasa Nonoshita
Mitsuru Ohkubo
Tetsuya Kato
Nobuhiko Kawanishi
Takashi Mita
Yoshikazu Iwasawa
Kouta Masutani
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of ECSP099062A publication Critical patent/ECSP099062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere al compuesto de fórmula I; en el que: R1 es un átomo de hidrógeno, F, CN, etc.; R2 es O, S, SO, SO2, etc.; R3 es un fenilo que puede estar sustituido; X2 es CH, N, etc.; W es el siguiente resto; en el que: W1, W2, y W3 son cada uno independientemente CH, N, etc., o una de sus sales ésteres farmacéuticamente aceptables.
EC2009009062A 2006-08-31 2009-01-13 Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a ECSP099062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
ECSP099062A true ECSP099062A (es) 2009-02-27

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009062A ECSP099062A (es) 2006-08-31 2009-01-13 Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Country Status (27)

Country Link
US (2) US7915263B2 (es)
EP (2) EP2062887B1 (es)
JP (3) JP2008081492A (es)
KR (1) KR20090055562A (es)
CN (1) CN101528731B (es)
AR (1) AR062585A1 (es)
AU (1) AU2007289609B2 (es)
CA (1) CA2657469C (es)
CL (1) CL2007002519A1 (es)
CO (1) CO6190529A2 (es)
CR (1) CR10553A (es)
EC (1) ECSP099062A (es)
ES (1) ES2389515T3 (es)
GT (1) GT200900008A (es)
HN (1) HN2009000113A (es)
IL (1) IL196497A0 (es)
MA (1) MA30719B1 (es)
MX (1) MX2009000390A (es)
NO (1) NO20091301L (es)
NZ (1) NZ574081A (es)
PE (1) PE20080835A1 (es)
RU (1) RU2437880C2 (es)
SV (1) SV2009003152A (es)
TW (1) TW200817363A (es)
UA (1) UA95972C2 (es)
WO (2) WO2008026769A1 (es)
ZA (1) ZA200900126B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411152B2 (ja) * 2008-02-22 2014-02-12 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
AU2009233315B2 (en) * 2008-03-31 2013-08-29 Sun Pharmaceutical Industries Ltd. An improved process for the preparation of morphinane analogues
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
CA2771190C (en) * 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2015175707A1 (en) 2014-05-13 2015-11-19 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
CN107251007B (zh) * 2015-03-25 2021-10-01 英特尔公司 集群计算服务确保装置和方法
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
IL148385A0 (en) 1999-09-10 2002-09-12 Merck & Co Inc Tyrosine kinase inhibitors
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
RU2332415C2 (ru) * 2001-04-27 2008-08-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, полезные в качестве ингибиторов протеинкиназы
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
EP1828165B1 (en) * 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
EP1833807A1 (en) 2005-01-05 2007-09-19 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006118231A1 (ja) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
PE20080835A1 (es) 2008-06-14
GT200900008A (es) 2010-10-04
NZ574081A (en) 2011-08-26
EP2062887B1 (en) 2012-07-04
NO20091301L (no) 2009-04-30
RU2437880C2 (ru) 2011-12-27
JP5256168B2 (ja) 2013-08-07
JPWO2008026769A1 (ja) 2010-01-21
EP2061782A1 (en) 2009-05-27
JP2008081492A (ja) 2008-04-10
EP2061782A4 (en) 2010-03-31
AU2007289609A1 (en) 2008-03-06
US20080058347A1 (en) 2008-03-06
US20100016335A1 (en) 2010-01-21
HN2009000113A (es) 2014-01-06
JP2010047602A (ja) 2010-03-04
AU2007289609B2 (en) 2012-02-02
WO2008026768A1 (en) 2008-03-06
ES2389515T3 (es) 2012-10-26
ZA200900126B (en) 2010-01-27
CN101528731A (zh) 2009-09-09
AR062585A1 (es) 2008-11-19
WO2008026769A1 (en) 2008-03-06
CA2657469A1 (en) 2008-03-06
UA95972C2 (ru) 2011-09-26
IL196497A0 (en) 2009-09-22
TW200817363A (en) 2008-04-16
JP4466782B2 (ja) 2010-05-26
US7915263B2 (en) 2011-03-29
EP2062887A1 (en) 2009-05-27
MA30719B1 (fr) 2009-09-01
CL2007002519A1 (es) 2008-02-08
RU2009111599A (ru) 2010-10-10
KR20090055562A (ko) 2009-06-02
EP2062887A4 (en) 2010-03-31
CO6190529A2 (es) 2010-08-19
CR10553A (es) 2009-06-28
MX2009000390A (es) 2009-01-29
SV2009003152A (es) 2009-04-28
CN101528731B (zh) 2014-05-07
CA2657469C (en) 2013-07-02

Similar Documents

Publication Publication Date Title
ECSP099062A (es) Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
HUE038158T2 (hu) Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként
GT200500240A (es) Nuevos herbicidas
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
CY2016028I2 (el) S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
DK2074120T3 (da) Tropan-forbindelser
CO6351740A2 (es) Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
DK2332909T3 (da) Hydroxybenzamidderivater og deres anvendelse som inhibitorer af hsp90
CR8595A (es) Inhibidor del dipeptidil-peptidasa
ATE521607T1 (de) Piperidinderivate als renin-inhibitoren
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
ATE521595T1 (de) Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor
ATE405553T1 (de) Heterocyclische verbindungen als inhibitoren von faktor viia
GT200500238A (es) Fenilaminotiazoles sustituidos y su uso
ATE459624T1 (de) Inhibitoren der reversen transkriptase des hiv
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
NI201000188A (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina.
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CO6331307A2 (es) Derivados de imidazo[1,2alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica
CO6331306A2 (es) Derivados de n-heterociclico-imidazo[1,2alfa]piridina-2-carboxamidas su preparacion y su aplicacion en terapeutica
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
ECSP077272A (es) Hexadecasacáridos biotinilados, su preparación y su utilización